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for preventing Trichinella spiralis infection. We have previously
reported that a recombinant Ts87 protein was considered as a
potential candidate vaccine for Trichinella spiralis. In this study
mucosal immune responses induced by SL7207/pvax1-Ts87 were
assessed.
Methods: We constructed a recombinant plasmid pvax1-Ts87,
and evaluated safety, stability of SL7207/pvax1-Ts87, a DNA
vaccine delivered in attenuated Salmonella typhimurium, and
immune responses induced by immunizing BALB/c mice orally
with SL7207/pvax1-Ts87 of 108 CFU dosage. After the ﬁnal boost,
mice were challenged orally with 500 Trichinella spiralis infec-
tive muscle larvae for per mouse.
Results: Oral immunization of mice with SL7207/pvax1-Ts87
elicited signiﬁcant elevation of intestinal secretory IgA and
serum anti-Ts87 IgG. The immunized mice exhibited a high ratio
of IgG1 to IgG2a. Splenocytes were isolated after the immu-
nization to determine the antigen-speciﬁc T-cell response by the
ELISPOT assay. The result showed that CD4+ T cells produced
IFN-γ, IL-4, IL-5, IL-6 and IL-10. Immunoﬂuorescent microscopy
revealed that the recombinant Ts87 protein was expressed in the
dendritic cells of mesenteric lymph nodes. Furthermore BALB/c
mice vaccinated with SL7207/pvax1-Ts87 demonstrated 29.8%
reduction in adult worm burden and muscle larval reduction
(34.2%) following Trichinella spiralis larvae challenge.
Conclusion: Our results demonstrated a SL7207/pvax1-Ts87 DNA
vaccine delivered in attenuated Salmonella typhimurium can
elicit speciﬁc immune response as well as provide effective
protection against Trichinella spiralis infection in mice.
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PL-004 Protective effect of bone-marrow-derived
mesenchymal stem cells on ischemic reperfusion
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transplantation
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Objective: To observe the distribution and amount of bone-
marrow-derived mesenchymal stem cells (BMSCs) after reduced-
size liver transplantation in rats and study the effect of BMSCs in
promoting the recovery of ischemic reperfusion injury.
Methods: 1. BMSCs were isolated from femur in the rat by the
density gradient centrifugation and puriﬁed. 2. All reduced-size
liver transplantation models were divided into 2 groups (each
group having 18 recipients)as follow: Wistar donor liver to Wistar
recipient, 1ml (5×106/ml) BMSCs of the third generation and
labeled (treat group) and 1ml PBS (control group) were injected
into portal vein, respectively. At the 2nd, 3rd and 7th day after
transplantation, liver and serum samples were collected. By us-
ing biochemistry, Immunohistochemistry, Flow CytoMeter and the
biochemical indicator were detect and counted. The distribution
of BMSCs in the frozen section was observed by ﬂuorescence.
The mechanism of the reparation of ischemic reperfusion injury
was explored through observation of the trace of CFSE-labeling
donator’s BMSCs in recipient’s body.
Results: The injured hepatic tissues were repaired. The green
ﬂuorescent cells were found in the recovery of the host liver tis-
sue, central veins and sinus hepaticus. The number of tetraploid
cell in treat group was signiﬁcantly inhibited in control group
(p=0.024).
Conclusion: BMSCs can successfully reside in the liver of rats and
the homing status of BMSCs is closely associated with quantity
of stem cells and the damage status of liver. BMSCs can protect
hepatic ischemic reperfusion injury.
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Objectives: Our recent study showed the potential for peginter-
feron alfa-2a and ribavirin combination therapy in these patients
– a high rate of HBsAg clearance was observed (11%) 24 weeks
post treatment in patients with HBeAg-negative disease. We
assessed HBsAg levels at baseline, during and after the end of
treatment.
Methods: HBsAg-positive patients coinfected with HCV received
peginterferon alfa-2a (180μg/week) for 48 weeks (in HCV geno-
type 1 in combination with ribavirin 1000/1200 mg/day) or for
24 weeks (for HCV genotype 2/3 in combination with ribavirin
800 mg/day). HBsAg was quantiﬁed at baseline, weeks 4, 12, end
of treatment (24 or 48 weeks) and 24 weeks post treatment (48
or 72 weeks) using the Abbott Architect assay. HBsAg data were
available for 120 of the 161 dual-infected patients.
Results: Of 120 patients, 74 received treatment for 48 weeks
and 46 received treatment for 24 weeks. Pretreatment median
serum HBsAg was 156 IU/mL. At the end of follow up, 14 patients
(11.7%) had cleared HBsAg. Baseline HBsAg levels in approxi-
mately 80% of patients clearing HBsAg at end of therapy or follow
up were low (<1 IU/mL). 21 (46%) patients who had received
therapy for 24 weeks achieved HBsAg levels <10 IU/mL at the
end of follow-up; 37 (50%) patients who had received therapy
for 48 weeks achieved HBsAg levels <10 IU/mL at the end of
follow-up.
Conclusions: HBV/HCV coinfected patients treated for 24 or 48
weeks with low baseline levels of HBsAg could potentially clear
HBsAg.
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Objective To construct a multiple detection platform for
macrolides and beta-lactamases resistant genes of clinical bac-
teria.
Methods To detected ermA, ermB, ermC, msrA genes for
macrolides and tem, shv, ctx-m-1 team, ctx-m-9 team genes
for beta-lactamases resistant genes screening by using multi-
plex real-time SYBR Green I PCR combining melt temperature
curve assay. Resistant genes were detected and the results were
compared with phenotype results and sequencing results.
Results All the resistance genes of positive bacteria were demon-
strated by the optimize multiplex detection platform. The sen-
sibility was 104 CFU for multiple resistant gene bateria and 103
CFU for single resistant gene bateria. The detection results of
